In premenopausal women with HR‐positive, HER2‐negative breast cancer, regardless of the recurrence score, ovarian function suppression (OFS) combined with tamoxifen or an aromatase inhibitor (AI) improves response to preoperative endocrine therapy compared with endocrine monotherapy. The gene discussed is CYP19A1; the disease is breast carcinoma.